PCN360 TREATMENT PATTERNS IN NON-SMALL CELL LUNG CANCER IN THE UNITED STATES: RESULTS OF THE CANCERMPACT SURVEY 2018

Abstract

To report the results of a survey of physicians that treat NSCLC patients, conducted in the United States of America in 2018. This survey (CancerMPact) recruited physicians within USA to answer an online questionnaire about how they treated their patients with NSCLC. Questions were detailed to cover aspects of the treatment for all stages of the disease. To be eligible, they had to have treated at least 24 NSCLC patients per month. The survey comprised 60 physicians with an average of 18.5 years of practice (range 5-30 years) after residence, who collectively had treated an average of 5,242 NSCLC patients per month before the survey. On average, each physician treated 87 NSCLC patients per month. For stage I patients, over 70% of the treatments performed by the surveyed physicians were based on surgery (alone or in combination with radiation and systemic therapy). For stage II/III disease, a strong preference for combined therapy (surgery/ radiation/ systemic therapy) was observed. For advanced/ stage IV patients, physicians strongly prefer to use systemic therapy alone, and often chose the regimen based on histology and biomarkers. This survey shows how physicians utilized many different treatments for their patients in 2018. As expected, most of the treatments were based on platinum-based combinations. However, the newer immunotherapy compounds, which were used as monotherapy in PD-L1 positive patients, and tyrosine kinase inhibitors, used for patients with specific driver mutation biomarkers, were also used in these respective patient populations.